A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INVZ SEC filings page.
Innoviz Technologies Ltd. (INVZ) reported $55.1M in revenue for fiscal year 2025, up 127.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
Revenue has reached commercial scale, but R&D-heavy operations still consume cash and require outside financing to fund growth.
In FY2025, revenue rose127.0% while gross margin improved 28.2 percentage points, yet operating loss was$67.7M because R&D was$56.5M —growth is not yet translating into operating break-even. This pairing matters: revenue expansion improved unit economics, but the cost base still absorbs more than gross profit can cover.
Operating cash flow was
Liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Innoviz Technologies Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Innoviz Technologies Ltd. held $18.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $47.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Innoviz Technologies Ltd. scores 18/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Innoviz Technologies Ltd. scores 50/100 on it among other emerging companies.
Innoviz Technologies Ltd. spent $56.5M on research and development in fiscal year 2025, which was 46.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Innoviz Technologies Ltd. scores 74/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Innoviz Technologies Ltd. scores 81/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Innoviz Technologies Ltd. scores 75/100 on it among other emerging companies.
Innoviz Technologies Ltd.'s cash, cash equivalents and investments came to $18.1M at the end of fiscal year 2025, against $60.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Innoviz Technologies Ltd. scores 34/100 among other emerging companies.
Innoviz Technologies Ltd. scores -8.35, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $797.8M against total assets of $138.5M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Innoviz Technologies Ltd. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Innoviz Technologies Ltd. reported a net loss of $67.8M while operations used $47.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Innoviz Technologies Ltd. earned -$0.10 per diluted share (EPS) in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Cash & Balance Sheet
Innoviz Technologies Ltd. recorded an outflow of $10.2M in free cash flow in Q4 2025, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Innoviz Technologies Ltd. held $8.6M in cash as of Q4 2025; no long-term debt figure is on record for that period.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
Innoviz Technologies Ltd. invested $1.0M in capex in Q4 2025, funding long-term assets and infrastructure. This represents a decrease of 12.7% from the same quarter a year earlier. Against the prior quarter it is up 263.6%.
Not reported for Q4 2025.
Not reported for Q4 2025.
INVZ Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, Diluted Shares (Avg).
INVZ Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q4'2420-F | Q3'246-K | Q2'246-K | Q4'2320-F | Q2'236-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $138.5M+4.8% | $151.1M | $151.1M-9.4% | $132.0M-39.8% | N/A | $166.8M-16.1% | $219.2M-14.2% | $198.8M-35.7% |
| Current Assets | $90.2M+9.2% | $102.2M | $100.9M-11.8% | $82.6M-48.5% | N/A | $114.4M-12.7% | $160.5M-14.4% | $131.1M-43.1% |
| Cash & Equivalents | $8.6M-65.9% | $7.9M-71.8% | $13.5M-43.6% | $25.4M-3.5% | $27.9M | $24.0M-30.1% | $26.3M-52.8% | $34.3M-31.7% |
| Short-Term Investments | $9.5M-20.8% | $9.4Mn/m | $9.3M-39.3% | $12.0M-10.3% | $0 | $15.3M-38.0% | $13.3M-68.0% | $24.6M+12.6% |
| Inventory | $3.3M+75.5% | $3.0M | $3.2M+82.6% | $1.9M+2.0% | N/A | $1.8M-61.8% | $1.9M-55.9% | $4.6M-1.4% |
| Accounts Receivable | $10.0M+65.1% | $19.8M | $11.6M+114.5% | $6.0M-18.3% | N/A | $5.4M+127.5% | $7.4M+319.7% | $2.4M+121.6% |
| Long-Term Investments | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0 | $1.2M-84.3% | $4.8M-38.6% | $7.8M-71.3% |
| Total Liabilities | $60.7M+14.3% | $61.4M | $58.0M+7.2% | $53.1M-19.4% | N/A | $54.1M-12.9% | $65.9M+4.0% | $62.1M+4.9% |
| Current Liabilities | $31.4M+13.2% | $32.1M | $28.3M+1.1% | $27.8M-25.4% | N/A | $28.0M-16.1% | $37.2M+14.8% | $33.4M+20.0% |
| Non-Current Liabilities | $29.3M+15.6% | $29.3M | $29.7M+13.7% | $25.4M-11.7% | N/A | $26.1M-9.1% | $28.7M-7.3% | $28.7M-8.5% |
| Total Equity | $77.7M-1.5% | $89.7M-3.2% | $93.1M-17.4% | $78.9M-48.5% | $92.6M | $112.7M-17.5% | $153.3M-20.2% | $136.7M-45.3% |
| Retained Earnings | -$797.8Mn/m | -$776.6M | -$761.2Mn/m | -$730.0Mn/m | N/A | -$686.6Mn/m | -$635.3Mn/m | -$577.8Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
INVZ Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q4'2420-F | Q3'246-K | Q2'246-K | Q4'2320-F | Q2'236-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.1Mn/m | -$13.7Mn/m | N/A | -$17.8M | -$16.5M | N/A | N/A | N/A |
| Depreciation & Amortization | $1.8M+12.9% | $1.4M-36.9% | N/A | $1.6M | $2.2M | N/A | N/A | N/A |
| Capital Expenditures | $1.0M-12.7% | $286K-76.0% | N/A | $1.2M | $1.2M | N/A | N/A | N/A |
| Free Cash Flow | -$10.2Mn/m | -$14.0Mn/m | N/A | -$19.0M | -$17.7M | N/A | N/A | N/A |
| Investing Cash Flow | $4.8M-68.4% | -$769K-103.8% | N/A | $15.1M | $20.1M | N/A | N/A | N/A |
| Financing Cash Flow | $5.0M+9076.4% | $8.9M+15182.8% | N/A | $55K | $58K | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
INVZ Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Innoviz Technologies Ltd. INVZ | FY2025 | $55.1M | -$67.8M | N/A | $42.9M | 55/100 |
| CarParts.com, Inc. PRTS | FY2025 | $547.5M | -$50.4M | -9.2% | $62.8M | 29/100 |
| Microvast Holdings, Inc. MVST | FY2025 | $427.5M | -$29.2M | -6.8% | $82.0M | 41/100 |
| Micware Co., Ltd. MWC | FY2026 | $140.3M | $10.3M | 7.3% | $77.8M | 71/100 |
| Stoneridge, Inc SRI | FY2025 | $861.3M | -$102.8M | -11.9% | $143.1M | 31/100 |
| China Automotive Systems, Inc. CAAS | FY2025 | $765.7M | $42.8M | 5.6% | $127.6M | 54/100 |
Where Innoviz Technologies Ltd. Ranks
Frequently Asked Questions
Innoviz Technologies Ltd. (INVZ) reported $55.1M in total revenue for fiscal year 2025. This represents a 127.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Innoviz Technologies Ltd. (INVZ) revenue grew by 127.0% year-over-year, from $24.3M to $55.1M in fiscal year 2025.
No, Innoviz Technologies Ltd. (INVZ) reported a net loss of $67.8M in fiscal year 2025.
Innoviz Technologies Ltd. (INVZ) had EBITDA of -$61.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Innoviz Technologies Ltd. (INVZ) had a gross margin of 23.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Innoviz Technologies Ltd. (INVZ) has a return on equity of -87.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Innoviz Technologies Ltd. (INVZ) recorded an outflow of $52.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Innoviz Technologies Ltd. (INVZ) recorded an outflow of $47.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Innoviz Technologies Ltd. (INVZ) had $138.5M in total assets as of fiscal year 2025, including both current and long-term assets.
Innoviz Technologies Ltd. (INVZ) invested $4.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Innoviz Technologies Ltd. (INVZ) invested $56.5M in research and development during fiscal year 2025.
Innoviz Technologies Ltd. (INVZ) had a current ratio of 2.87 as of fiscal year 2025, which is generally considered healthy.
Innoviz Technologies Ltd. (INVZ) had a liabilities-to-equity ratio of 0.78 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Innoviz Technologies Ltd. (INVZ) had a return on assets of -49.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Innoviz Technologies Ltd. (INVZ) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $42.9M as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Innoviz Technologies Ltd. (INVZ) trades at 0.8x sales, its market capitalization divided by $55.1M revenue, FY2025. The market capitalization is $42.9M as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Innoviz Technologies Ltd. (INVZ) held $18.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $47.9M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Innoviz Technologies Ltd. (INVZ) has an Altman Z-Score of -8.35, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Innoviz Technologies Ltd. (INVZ) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Innoviz Technologies Ltd. (INVZ) reported a net loss of $67.8M while operations used $47.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Innoviz Technologies Ltd. (INVZ) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.